Please ensure Javascript is enabled for purposes of website accessibility

Bayer's Prostate Cancer Drug Scores a Late-Stage Clinical Win

By Mark Prvulovic - Jan 30, 2020 at 4:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Both Johnson & Johnson as well as Pfizer could face new competition in the prostate cancer market.

Bayer (BAYR.Y -0.97%) announced on Thursday that its prostate cancer drug, Nubeqa, just scored a major late-stage clinical victory. The treatment, which is a relative latecomer to the prostate cancer scene in comparison to some of its rivals, showed strong results in delaying tumor growth in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

The phase 3 Aramis trial showed that patients that had taken Nubeqa alongside androgen deprivation therapy (ADT) had improved survival times in comparison to nmCRPC patients that were taking just a placebo alongside ADT. Although the complete data won't be available until later at a future medical meeting, it was confirmed that the study met both its primary and secondary endpoints of improving patient survival time.

A man holding a prostate cancer ribbon in his palm.

Image source: Getty Images.

Bayer's top-selling drugs, a macular-degeneration treatment called Eylea and a blood-thinner known as Xarelto, are fast approaching patent expiration. As such, the pharmaceutical giant is doing its best to push sales of its newer drugs, such as Nubeqa.

Rival competitors

Both Johnson & Johnson's (JNJ 1.46%) Erleada as well as Pfizer's (PFE 3.00%) Xtandi are drugs that already target patients with prostate cancer. However, it's uncertain whether these new results will be enough to give the drug an edge over its competitors. Johnson & Johnson announced last year that Erleada alongside ADT reduced the chance of patient death by 25% in comparison to just the ADT-placebo combo.

Bayer's Nubeqa will likely also face challenges from healthcare watchdog groups, who have refused to accept other prostate cancer drugs due to their cost effectiveness. England's top drug watchdog, the National Institute for Health and Care Excellence (NICE), recently turned down Pfizer's Xtandi for exactly that reason.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bayer Stock Quote
Bayer
BAYR.Y
$15.23 (-0.97%) $0.15
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.59 (3.00%) $1.50
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$182.29 (1.46%) $2.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.